1. Home
  2. COLL vs BFC Comparison

COLL vs BFC Comparison

Compare COLL & BFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • BFC
  • Stock Information
  • Founded
  • COLL 2002
  • BFC 1894
  • Country
  • COLL United States
  • BFC United States
  • Employees
  • COLL N/A
  • BFC N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • BFC Major Banks
  • Sector
  • COLL Health Care
  • BFC Finance
  • Exchange
  • COLL Nasdaq
  • BFC Nasdaq
  • Market Cap
  • COLL 1.0B
  • BFC 990.6M
  • IPO Year
  • COLL 2015
  • BFC N/A
  • Fundamental
  • Price
  • COLL $29.13
  • BFC $102.52
  • Analyst Decision
  • COLL Strong Buy
  • BFC Hold
  • Analyst Count
  • COLL 5
  • BFC 1
  • Target Price
  • COLL $43.60
  • BFC $104.00
  • AVG Volume (30 Days)
  • COLL 294.2K
  • BFC 12.6K
  • Earning Date
  • COLL 02-27-2025
  • BFC 04-15-2025
  • Dividend Yield
  • COLL N/A
  • BFC 1.61%
  • EPS Growth
  • COLL 757.11
  • BFC N/A
  • EPS
  • COLL 2.16
  • BFC 6.50
  • Revenue
  • COLL $599,245,000.00
  • BFC $158,246,000.00
  • Revenue This Year
  • COLL $13.25
  • BFC N/A
  • Revenue Next Year
  • COLL $17.67
  • BFC $6.64
  • P/E Ratio
  • COLL $13.47
  • BFC $15.81
  • Revenue Growth
  • COLL 9.62
  • BFC N/A
  • 52 Week Low
  • COLL $28.39
  • BFC $74.90
  • 52 Week High
  • COLL $42.29
  • BFC $110.49
  • Technical
  • Relative Strength Index (RSI)
  • COLL 37.61
  • BFC 52.47
  • Support Level
  • COLL $29.39
  • BFC $101.09
  • Resistance Level
  • COLL $30.39
  • BFC $103.21
  • Average True Range (ATR)
  • COLL 1.00
  • BFC 1.79
  • MACD
  • COLL -0.24
  • BFC 0.01
  • Stochastic Oscillator
  • COLL 11.04
  • BFC 68.37

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About BFC Bank First Corporation

Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.

Share on Social Networks: